- “Community Routes: Access to Mental Health Care” helps
uninsured patients access healthcare for anxiety and depression,
and is a partnership between Direct Relief, the National
Association of Free and Charitable Clinics (NAFC) and Teva
Pharmaceuticals
- The expansion of medicine donations for anxiety and depression
into seven new states across the United States has the potential
to extend the program’s reach to more than 650,000 uninsured
patients through 400+ eligible clinics
- The program provides access to a portfolio of donated medicines
for anxiety and depression, valued at over $17 million; Teva has
committed $2 million of grant funding over two years to free and
charitable clinics that care for uninsured patients
Direct Relief, the National Association of Free and Charitable
Clinics (NAFC), and Teva Pharmaceuticals, U.S. affiliate of Teva
Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today
announced an expansion of medicine donations through their
collaborative mental health access program into seven new states to
advance access to healthcare for uninsured patients seeking
treatment for anxiety and depression.
Through “Community Routes: Access to Mental Health Care,” Teva
will continue to provide free and charitable clinics with $2
million in grant funding over two years and make available, on a
charitable basis, a portfolio of commonly used generic medications
that treat anxiety and depression. Medicines will be available to
free and charitable clinics and pharmacies in Direct Relief's
network. The annual value of these medicines provided by Teva is
over $17 million this year alone, as determined by their wholesale
acquisition cost (WAC).
This announcement expands the program’s medicine donations into
seven new states: Alabama, Georgia, Mississippi, North Carolina,
South Carolina, Texas and Virginia, increasing the program’s
potential reach to more than 650,000 uninsured patients through
400+ eligible free and charitable clinics across 10 total states.
The seven new states announced today were selected based on the
program’s ability to maximize patient impact, which was determined
by assessing unmet need and the presence of a strong network of
partner free and charitable clinics in each state.
The program was launched in June 2022, following which the pilot
states of Florida, New Jersey and California received product
donations and subsequently grant funding to selected clinics.
“As the need for mental health support surges, access to care
for people living with anxiety and depression is more pressing than
ever,” said Thomas Tighe, CEO and President of Direct Relief.
“Direct Relief is deeply grateful to Teva for demonstrating such
leadership and dedication and welcomes the opportunity to
collaborate with the NAFC and Teva to provide patients with the
resources necessary to lead happier and healthier lives.”
"We continue to face a mental health crisis across the U.S. and
those directly impacted deserve access to treatment, regardless of
background or economic status," said Sven Dethlefs, PhD, Executive
Vice President, North America Commercial at Teva. "Teva is
committed to the pursuit of health equity and will continue to
bring forward its expertise and resources to help ensure medication
availability for anxiety and depression."
Nicole Lamoureux, President and CEO of NAFC said, “Free and
Charitable Clinics are critical to providing care to underserved
communities. We’re appreciative of Direct Relief and Teva’s
partnership as we chart new strategies to alleviate healthcare
inequities and provide access to medicine for some of the most
vulnerable among us.”
"Since the pandemic began, addressing mental health has
continued to be a priority for our clinic,” shared Fred
Bauermeister, Executive Director at Free Clinic of Simi Valley, in
California. “With these donations, we have been able to increase
access to medications that treat anxiety and depression for the
uninsured or underinsured members of our community, generating both
progress and a sense of hope."
A third of adults in the U.S. show symptoms of anxiety,
depression, or both.1 Notably, more than 5.5 million adults with a
mental illness are uninsured, and almost a third of all adults with
a mental illness reported they were not able to receive the
treatment they needed.2 Additionally, as a result of the COVID-19
pandemic, racial minorities have experienced higher rates of
depression and anxiety compared to their white counterparts. In
fact, depression was 15 to 23 times more prevalent for those who
identify as Black, Hispanic or Asian.3
About Direct Relief A humanitarian organization committed
to improving the health and lives of people affected by poverty and
emergencies, Direct Relief delivers lifesaving medical resources
throughout the U.S. and world to communities in need—without regard
to politics, religion, or ability to pay. For more information,
visit https://www.DirectRelief.org.
About National Association of Free and Charitable Clinics
National Association of Free and Charitable Clinics (NAFC) is the
only nonprofit 501c (3) organization whose mission is solely
focused on the issues and needs of the medically underserved
throughout the nation and the more than 1,400 Free and Charitable
Clinics that serve them. The NAFC has earned the Platinum Seal of
Transparency from GuideStar and a 4-star rating from Charity
Navigator. Founded in 2001 and headquartered near Washington, D.C.,
the NAFC is working to ensure that the medically underserved have
access to affordable quality health care and strives to be a
national voice promoting quality health care for all. For more
information about the NAFC, please visit www.nafcclinics.org.
About Teva Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve
people’s lives for more than a century. We are a global leader in
generic and innovative medicines with a portfolio consisting of
over 3,500 products in nearly every therapeutic area. Around 200
million people around the world take a Teva medicine every day, and
are served by one of the largest and most complex supply chains in
the pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of innovative and
biopharmaceutical products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
which are based on management’s current beliefs and expectations
and are subject to substantial risks and uncertainties, both known
and unknown, that could cause our future results, performance or
achievements to differ significantly from that expressed or implied
by such forward-looking statements. You can identify these
forward-looking statements by the use of words such as “should,”
“expect,” “anticipate,” “estimate,” “target,” “may,” “project,”
“guidance,” “intend,” “plan,” “believe” and other words and terms
of similar meaning and expression in connection with any discussion
of future operating or financial performance. Important factors
that could cause or contribute to such differences include risks
relating to medicine donations through our collaborative mental
health access program; our ability to successfully compete in the
marketplace, including our ability to develop and commercialize
biopharmaceutical products, competition for our innovative
medicines, including AUSTEDO®, AJOVY® and COPAXONE®, our ability to
achieve expected results from investments in our product pipeline,
our ability to develop and commercialize additional pharmaceutical
products, and the effectiveness of our patents and other measures
to protect our intellectual property rights; our substantial
indebtedness; our business and operations in general, including,
the impact of global economic conditions and other macroeconomic
developments and the governmental and societal responses thereto,
and costs and delays resulting from the extensive pharmaceutical
regulation to which we are subject; compliance, regulatory and
litigation matters, including failure to comply with complex legal
and regulatory environments; other financial and economic risks;
and other factors discussed in our Annual Report on Form 10-K for
the year ended December 31, 2022, including in the section
captioned “Risk Factors.” Forward-looking statements speak only as
of the date on which they are made, and we assume no obligation to
update or revise any forward-looking statements or other
information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
_______________________________ 1 “Anxiety and Depression.”
Centers for Disease Control and Prevention, 2023,
https://www.cdc.gov/nchs/covid19/pulse/mental-health.htm 2 “The
State of Mental Health in America.” Mental Health America, 2023,
https://mhanational.org/issues/state-mental-health-america 3 “The
mental health burden of racial and ethnic minorities during the
COVID-19 pandemic.” National Institutes of Health, 2022,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365178/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230503005145/en/
Direct Relief United States Tony Morain
TMorain@directrelief.org
NAFCUnited States Kerry Thompson
kerry@nafcclinics.org
Teva United States Yonatan Beker
Yonatan.Beker@tevapharm.com (973) 2647378
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Aug 2023 bis Sep 2023
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Sep 2022 bis Sep 2023
